ATE393243T1 - Diagnostisches verfahren der mastozytose - Google Patents

Diagnostisches verfahren der mastozytose

Info

Publication number
ATE393243T1
ATE393243T1 AT04715423T AT04715423T ATE393243T1 AT E393243 T1 ATE393243 T1 AT E393243T1 AT 04715423 T AT04715423 T AT 04715423T AT 04715423 T AT04715423 T AT 04715423T AT E393243 T1 ATE393243 T1 AT E393243T1
Authority
AT
Austria
Prior art keywords
mastocytosis
mutation
detected
kit
diagnostic procedure
Prior art date
Application number
AT04715423T
Other languages
English (en)
Inventor
Jean-Pierre Kinet
Alain Moussy
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Application granted granted Critical
Publication of ATE393243T1 publication Critical patent/ATE393243T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT04715423T 2003-02-27 2004-02-27 Diagnostisches verfahren der mastozytose ATE393243T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44986103P 2003-02-27 2003-02-27

Publications (1)

Publication Number Publication Date
ATE393243T1 true ATE393243T1 (de) 2008-05-15

Family

ID=32927581

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04715423T ATE393243T1 (de) 2003-02-27 2004-02-27 Diagnostisches verfahren der mastozytose

Country Status (7)

Country Link
US (1) US20080025916A1 (de)
EP (1) EP1597398B1 (de)
JP (1) JP2006519220A (de)
AT (1) ATE393243T1 (de)
CA (1) CA2517308A1 (de)
DE (1) DE602004013283D1 (de)
WO (1) WO2004076693A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1653934B1 (de) * 2003-08-15 2008-05-14 AB Science Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
EP1684750B1 (de) 2003-10-23 2010-04-28 AB Science 2-aminoaryloxazol-verbindungen als tyrosinkinase-hemmer
AU2006231929B2 (en) * 2005-04-04 2012-09-06 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
NZ563866A (en) 2005-05-09 2011-03-31 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
NZ578944A (en) 2007-02-13 2011-03-31 Ab Science PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS SUCH AS 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide AS KINASE INHIBITORS
US8183263B2 (en) 2007-05-22 2012-05-22 Achillion Pharmaceuticals, Inc. Heteroaryl substituted thiazoles
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339100B1 (en) * 1999-12-29 2002-01-15 The Trustees Of Columbia University In The City Of New York Methods for inhibiting mastocytosis
GB0108606D0 (en) * 2001-04-05 2001-05-23 Novartis Ag Organic compounds
JP2005500041A (ja) * 2001-06-29 2005-01-06 アブ サイエンス 強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
EP1401411A2 (de) * 2001-06-29 2004-03-31 AB Science Verwendung von tyrosin kinase hemmern zur behandlung von knochenschwund
EP1471907B1 (de) * 2001-06-29 2008-07-16 AB Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
JP2005503361A (ja) * 2001-06-29 2005-02-03 アブ サイエンス 肥満細胞症治療のための強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤の使用
CA2494695C (en) * 2002-08-02 2011-04-05 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors

Also Published As

Publication number Publication date
DE602004013283D1 (de) 2008-06-05
EP1597398A1 (de) 2005-11-23
JP2006519220A (ja) 2006-08-24
EP1597398B1 (de) 2008-04-23
CA2517308A1 (en) 2004-09-10
WO2004076693A1 (en) 2004-09-10
US20080025916A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
ATE442592T1 (de) Detektion und/oder beobachtung von synuclein- assoziierten krankheiten
Cunningham et al. Development of a condition‐specific quality of life measure for patients with dentofacial deformity: II. Validity and responsiveness testing
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE447878T1 (de) Verfahren und vorrichtung zur augenverfolgung
ATE311876T1 (de) Hochselektive butyrylcholinesterase inhibitoren zur behandlung und zur diagnose von demenz und alzheimers krankheit
WO2006041678A3 (en) Pharmaceutical treatment effectiveness analysis computer system and methods
WO2003107252A3 (en) METHOD AND SYSTEM FOR MONITORING PATIENT CARE
DE69434152D1 (de) Vorrichtung zur beurteilungshilfe des kardiovaskulären zustandes eines patienten
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
CY1110503T1 (el) Πενταμιδινη για θεραπεια καρκινου
ATE393243T1 (de) Diagnostisches verfahren der mastozytose
ATE557087T1 (de) Verfahren und kit zum nachweis von sklerose verursachenden proliferativen erkrankungen und/oder heilmittel gegen sklerose verursachende proliferative erkrankungen sowie verfahren und kit zur identifizierung einer bei der vorbeugung und/oder behandlung von sklerose verursachenden proliferativen erkrankungen wirksamen substanz
SE0301825D0 (sv) Method and arrangement relating to testing implants
WO2002095358A3 (en) System and method for monitoring or treating a health condition
ATE548973T1 (de) Beurteilung kognitiver beeinträchtigung
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
FI933291A0 (fi) Foerfarande foer paovisning av anti-rna-antikroppar
DE60231896D1 (de) Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
ATE430517T1 (de) Verfahren und geräte zur beobachtung und aufzeichnung von unregelmässigkeiten der makula und des nahen retinafelds
DE602006005635D1 (de) Vorrichtung und verfahren zum automatischen prüfen der temperaturempfindlichkeit eines patienten
EP1611251A4 (de) Therapeutische, prophylaktische und diagnostische wirkstoffe
EP1363528A4 (de) Verfahren zur diagnose und behandlung von herzerkrankungen
ATE390435T1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
DE60323954D1 (de) Ex-vivo-verfahren zur bestimmung der cetp-aktivität und der wirksamkeit der behandlung von herzerkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties